Literature DB >> 23795808

Paradoxical oncogenesis: are all BRAF inhibitors equal?

Alexander M Menzies1, Richard F Kefford, Georgina V Long.   

Abstract

Cutaneous squamous cell carcinoma (cSCC) is a concerning toxicity with BRAF inhibitors in the treatment for melanoma. While the two drugs shown to improve survival, vemurafenib, and dabrafenib, have similar efficacy, the reported rates of cSCC are quite different. Drawing upon preclinical and clinical trial data, this article discusses the potential factors behind the different cSCC incidences reported with the two BRAF inhibitors and provides a strategic approach to understand this issue further.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  BRAF inhibitor; dabrafenib; melanoma; secondary malignancy; squamous cell carcinoma; vemurafenib

Mesh：

Substances：

Year:  2013        PMID： 23795808     DOI： 10.1111/pcmr.12132

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN： 1755-1471            Impact factor:   4.693


  19 in total

Review 1.  Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.

Authors:  Darshil J Shah; Roxana S Dronca
Journal:  Mayo Clin Proc       Date:  2014-04       Impact factor: 7.616

Review 2.  Biology and treatment of BRAF mutant metastatic melanoma.

Authors:  Benjamin Y Kong; Matteo S Carlino; Alexander M Menzies
Journal:  Melanoma Manag       Date:  2016-02-12

Review 3.  Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib.

Authors:  Alicja Puszkiel; Gaëlle Noé; Audrey Bellesoeur; Nora Kramkimel; Marie-Noëlle Paludetto; Audrey Thomas-Schoemann; Michel Vidal; François Goldwasser; Etienne Chatelut; Benoit Blanchet
Journal:  Clin Pharmacokinet       Date:  2019-04       Impact factor: 6.447

4.  Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor‒Resistant BRAFV600E/NRASQ61K Melanoma Enhancing Tumor Growth and Metastasis in a Bioluminescent Murine Model.

Authors:  Jana Jandova; Georg T Wondrak
Journal:  J Invest Dermatol       Date:  2021-10-21       Impact factor: 7.590

5.  MEK Is a Therapeutic and Chemopreventative Target in Squamous Cell Carcinoma.

Authors:  Charles H Adelmann; Kimberly A Truong; Roger J Liang; Varun Bansal; Leah Gandee; Rachael C Saporito; Woojin Lee; Lili Du; Courtney Nicholas; Marco Napoli; Barbara Mino; Andrew P South; Charlotte M Proby; Irene M Leigh; Cristian Coarfa; Elsa R Flores; Kenneth Y Tsai
Journal:  J Invest Dermatol       Date:  2016-06-09       Impact factor: 8.551

6.  Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.

Authors:  Douglas B Johnson; Alexander M Menzies; Lisa Zimmer; Zeynep Eroglu; Fei Ye; Shilin Zhao; Helen Rizos; Antje Sucker; Richard A Scolyer; Ralf Gutzmer; Helen Gogas; Richard F Kefford; John F Thompson; Jürgen C Becker; Carola Berking; Friederike Egberts; Carmen Loquai; Simone M Goldinger; Gulietta M Pupo; Willy Hugo; Xiangju Kong; Levi A Garraway; Jeffrey A Sosman; Antoni Ribas; Roger S Lo; Georgina V Long; Dirk Schadendorf
Journal:  Eur J Cancer       Date:  2015-11-19       Impact factor: 9.162

7.  EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile.

Authors:  Jiayin Zhang; Biao Lu; Dong Liu; Ru Shen; Yinfa Yan; Liuqing Yang; Minsheng Zhang; Lei Zhang; Guoqing Cao; Hu Cao; Beibei Fu; Aishen Gong; Qiming Sun; Hong Wan; Lianshan Zhang; Weikang Tao; Jingsong Cao
Journal:  Cancer Biol Ther       Date:  2016-01-25       Impact factor: 4.742

Review 8.  Systemic treatments for metastatic cutaneous melanoma.

Authors:  Sandro Pasquali; Andreas V Hadjinicolaou; Vanna Chiarion Sileni; Carlo Riccardo Rossi; Simone Mocellin
Journal:  Cochrane Database Syst Rev       Date:  2018-02-06

9.  BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling.

Authors:  Harina Vin; Sandra S Ojeda; Grace Ching; Marco L Leung; Vida Chitsazzadeh; David W Dwyer; Charles H Adelmann; Monica Restrepo; Kristen N Richards; Larissa R Stewart; Lili Du; Scarlett B Ferguson; Deepavali Chakravarti; Karin Ehrenreiter; Manuela Baccarini; Rosamaria Ruggieri; Jonathan L Curry; Kevin B Kim; Ana M Ciurea; Madeleine Duvic; Victor G Prieto; Stephen E Ullrich; Kevin N Dalby; Elsa R Flores; Kenneth Y Tsai
Journal:  Elife       Date:  2013-11-05       Impact factor: 8.140

10.  Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg Study.

Authors:  Henner Stege; Maximilian Haist; Michael Schultheis; Maria Isabel Fleischer; Peter Mohr; Friedegund Meier; Dirk Schadendorf; Selma Ugurel; Elisabeth Livingstone; Lisa Zimmer; Rudolf Herbst; Claudia Pföhler; Katharina Kähler; Michael Weichenthal; Patrick Terheyden; Dorothée Nashan; Dirk Debus; Martin Kaatz; Fabian Ziller; Sebastian Haferkamp; Andrea Forschner; Ulrike Leiter; Alexander Kreuter; Jens Ulrich; Johannes Kleemann; Fabienne Bradfisch; Stephan Grabbe; Carmen Loquai
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.